Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.

Journal of gastroenterology and hepatology - 1 Mar 2006

Kokoglu Omer Faruk, Uçmak Hasan, Hosoglu Salih, Cetinkaya Ali, Kantarceken Bulent, Buyukbese Mehmet Akif, Isik Ismet Onder

Abstract excerpt

BACKGROUND AND AIM: Hepatitis C virus (HCV) is prevalent in hemodialysis (HD) patients. These patients experience more side-effects with antiviral treatment. The aim of the present study was to evaluate the efficacy and tolerability of pegylated interferon (PEG-IFN) alpha-2a in chronic hemodialysis patients with chronic hepatitis C. METHODS: Twenty-five patients were included into the study. All of the patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Kidney Failure, Chronic

Share to Liver Function Tests

Share to Polyethylene Glycols

Share to Renal Dialysis

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 16638102
DOI: 10.1111/j.1440-1746.2005.04008.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.PMID 16638102Read ↗

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.Semantic proximity Read ↗

The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.Semantic proximity Read ↗

Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis.Semantic proximity Read ↗

Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.Semantic proximity Read ↗

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Semantic proximity Read ↗

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.Semantic proximity Read ↗

Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Semantic proximity Read ↗

The Efficacy of the Direct-Acting Antiviral Combination in Hemodialysis Patients With Chronic Hepatitis C Virus Genotype 1 InfectionSemantic proximity Read ↗

Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.Semantic proximity Read ↗

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.Semantic proximity Read ↗

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.